TSNDF (TerrAscend) EBIT: $43.2 Mil (TTM As of Mar. 2026)


TSNDF TerrAscend Corp TSNDF
32 GF Score
Price $0.65
GF Value $0.99
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is TerrAscend EBIT?

TerrAscend TSNDF +2.79% 32 EBIT is $43.2 Mil as of Mar. 2026. GuruFocus rates TSNDF with a GF Score™ of 32/100 and a GF Value™ of $0.99 (Possible Value Trap). The stock has 5 warning signs investors should review.

TerrAscend's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $13.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $43.2 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TerrAscend's annualized ROC % for the quarter that ended in Mar. 2026 was 0.00%. TerrAscend's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 32.09%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TerrAscend's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 10.37%.


TerrAscend  (OTCPK:TSNDF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TerrAscend's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=46.084 * ( 1 - 100% )/( (482.035 + 470.283)/ 2 )
=0/476.159
=0.00 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

TerrAscend's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=52.696/( ( (156.623 + max(7.834, 0)) + (157.811 + max(6.171, 0)) )/ 2 )
=52.696/( ( 164.457 + 163.982 )/ 2 )
=52.696/164.2195
=32.09 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(15.143 + 34.054 + 21.38) - (45.167 + 3.993 + 13.583)
=7.834

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.024 + 36.232 + 11.299) - (44.054 + 4.393 + 6.937)
=6.171

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TerrAscend's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=43.178/416.317
=10.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TerrAscend EBIT Related Terms


TerrAscend EBIT Historical Data

* Premium members only.

The historical data trend for TerrAscend's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TerrAscend EBIT Chart

TerrAscend Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.52 -271.13 27.81 38.58 41.27

TerrAscend Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.26 12.15 10.37 7.48 13.17

TSNDF vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, TerrAscend's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TerrAscend EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TerrAscend's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TerrAscend's EV-to-EBIT falls into.


TSNDF
32GF Score
TerrAscend Corp TSNDF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TerrAscend EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $43.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $43.2 Mil mean?
TerrAscend (TSNDF) has a EBIT of $43.2 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TerrAscend.
Is TerrAscend's EBIT too high?
TerrAscend's current EBIT is $43.2 Mil. Overall, TerrAscend has a GF Score™ of 32/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TerrAscend's EBIT compare to ZTS?
TerrAscend's EBIT of $43.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on TerrAscend. TerrAscend's current EBIT is $43.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TerrAscend stock overvalued right now?
Based on GuruFocus' analysis, TerrAscend (TSNDF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.99, compared to a current price of $0.65 — trading 34.8% below its estimated fair value. The current EBIT is $43.2 Mil. TerrAscend's overall GF Score™ is 32/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For TerrAscend (TSNDF), the current EBIT is $43.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TerrAscend (TSNDF) Overvalued in 2026?

Based on GuruFocus' analysis, TerrAscend stock appears to be undervalued. The current stock price of $0.65 is trading 34.8% below its estimated GF Value™ of $0.99. GuruFocus considers TerrAscend to be Possible Value Trap.

Key valuation signals for TSNDF:

  • EBIT: $43.2 Mil
  • GF Value™: $0.99 vs. price of $0.65 (34.8% below fair value)
  • GF Score™: 32/100 with 5 warning signs

No single metric tells the full story. See the TSNDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


TerrAscend Business Description

Other Exchanges TED:GermanyTSND:Canada
Address 77 City Centre Drive, Suite 501, East Tower, Mississauga, ON, CAN, L5B 1M5
TerrAscend Corp is a company focused on creating and delivering cannabis products and services that meet the evolving needs of its patients. It also provides education and support programs to physicians and patients through healthcare professionals. In addition, the firm operates in California, Maryland, New Jersey, and Pennsylvania, with retail operations in Ohio and Canada. It operates The Apothecarium and other dispensary retail locations as well as scaled cultivation, processing, and manufacturing facilities in its core markets. The firm has one operating segment, being the cultivation, production, and sale of cannabis products, with subsidiaries located in Canada and the United States. The company generates key revenue from the United States.
32GF Score

Get the complete analysis for TSNDF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.99
GF Value